Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR3 | P49682 | 1/20 | 0.33 |
| ▸ | CHRNA7 | P36544 | 4/20 | 0.32 |
| ▸ | KIF18A | Q8NI77 | 2/20 | 0.32 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.31 |
| ▸ | HTR3A | P46098 | 1/20 | 0.31 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.31 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20249370 | 0.78 | SCD (0.36) | CXCR3CHRM4 | |
| SCHEMBL20249382 | 0.75 | CHRNA7 (0.38) | CHRNA7HTR3ACHRNB4CHRNA3 | |
| SCHEMBL20038163 | 0.68 | OGA (0.39) | HTR3A | |
| SCHEMBL18291571 | 0.67 | CHRNA7 (0.41) | CHRNA7HTR3ACHRNB4CHRNA3 | |
| SCHEMBL20255108 | 0.67 | SMPD3 (0.37) | — | |
| SCHEMBL20249355 | 0.65 | SOS1 (0.33) | — | |
| SCHEMBL20249290 | 0.65 | PTPN11 (0.43) | — | |
| SCHEMBL20255570 | 0.63 | CHRNA7 (0.37) | CHRNA7HTR3ACHRNB4CHRNA3 | |
| SCHEMBL20255107 | 0.62 | GAA (0.39) | — | |
| SCHEMBL20249350 | 0.62 | KMT2A (0.38) | CHRNA7HTR3ACHRNB4CHRNA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180161329-A1 | PYRIDO[3,4-D]PYRIMIDINE DERIVATIVE AND PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | TEIJIN PHARMA LIMITED (JP) | 2018-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180161329-A1 | PYRIDO[3,4-D]PYRIMIDINE DERIVATIVE AND PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | CDK4, CDK6, CDK16 | CXCR3 1880/4885CHRNA7 4757/4885KIF18A 864/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.